Is Bortezomib 2 mg a type of chemotherapy?
Bortezomib 2 mg is a proteasome inhibitor, which is a type of cancer treatment medicine. Cells contain proteasomes. They aid in the breakdown of proteins that the cell doesn’t need. Bortezomib restrains the proteasomes, making proteins collect inside the cell.
What is bortezomib injection used for?
The medication bortezomib is used to treat multiple myeloma (a type of cancer of the bone marrow). Bortezomib is also used to treat patients with mantle cell lymphoma (fast-growing cancer that begins in the cells of the immune system). Bortezomib has a place in the class of meds known as antineoplastic specialists.
What are the Bortezomib 2 mg side effects?
- The injection site may cause dizziness.
- lack of appetite.
- or pain or redness.
- Common adverse effects include nausea, vomiting, and diarrhea. Your primary care physician might prescribe medicine to forestall or mitigate sickness, heaving, or looseness of the bowels in certain conditions.For more details Click Here.
How frequently is Bortezomib 2 mg administered?
VELCADE is given two times a week for two weeks (Days 1, 4, 8, and 11), then, at that point, a ten-dawn from Days 12 to 21. Two further VcR-CAP cycles are indicated for patients who had a response to cycle 6. A minimum of 72 hours should elapse between VELCADE dosages.
Is Bortezomib 2 mg an oral medication?
Because bortezomib is supplied parenterally, the new medicine provides the convenience of oral administration. Initially, it was only accessible as an intravenous infusion, but it is now also available as a subcutaneous formulation.
How long does Bortezomib 2 mg stay in the body?
After a single dose, bortezomib is rapidly transported into tissues, with an initial plasma distribution half-life of fewer than 10 minutes and a terminal elimination half-life of more than 40 hours.
Is bortezomib linked to anemia?
Side effects that may occur. Nausea, diarrhea, thrombocytopenia, neutropenia, peripheral neuropathy, lethargy, neuralgia, anemia, leukopenia, constipation, vomiting, lymphopenia, rash, pyrexia, and anorexia are the most prevalent adverse effects of Velcade (reported at a 20% incidence in clinical research).